Combination is named as an intervention in 4 current clinical trials in our China, Italy, Denmark and Egypt registers. 3 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Sun Yat-sen University (1). The most-studied condition is Type 2 Diabetes.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
NCT04341181 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasms
|
Phase 2 | Recruiting | Ulrik Lassen | Denmark |
|
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
NCT06008691 · ClinicalTrials.gov ↗ · Non-Hodgkin Lymphoma, B-cell
|
Observational | Recruiting | Fondazione Italiana Linfomi - ETS | Italy |
|
Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
NCT07390851 · ClinicalTrials.gov ↗ · Myofascial Pain Dysfunction Syndrome
|
Not applicable | Recruiting | Cairo University | Egypt |
|
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
NCT07003191 · ClinicalTrials.gov ↗ · Type 2 Diabetes
|
Observational | Active, closed | Sun Yat-sen University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Sun Yat-sen University | 1 |
| Fondazione Italiana Linfomi - ETS | 1 |
| Ulrik Lassen | 1 |
| Cairo University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in Italy | 1 | 1 |
| Clinical trials in Denmark | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China, Italy, Denmark and Egypt registers name Combination as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 1 with sites in Italy, 1 with sites in Denmark and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sun Yat-sen University (1), Fondazione Italiana Linfomi - ETS (1), Ulrik Lassen (1) and Cairo University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Combination works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Combination works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Combination (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.